clinical trial · NCT07796256
A Phase 2 Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Suzhou Sanegene Bio Inc.·phase2·not yet recruiting·n = 24
PNH - Paroxysmal Nocturnal HemoglobinuriaSGB-9768
brief summary
This is a multicenter, randomized, open-Label Phase II study to evaluate the efficacy and safety of multiple doses of SGB-9768 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
started
Oct 31, 2026
primary completion
Aug 31, 2027
completion
Dec 31, 2027
last updated
Sep 1, 2026
official title
A Multicenter, Randomized, Open-Label Phase II Study to Evaluate the Efficacy and Safety of Multiple Doses of SGB-9768 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol